<DOC>
	<DOCNO>NCT02099994</DOCNO>
	<brief_summary>The study part long-term aim develop effective HIV-1 vaccine evaluate safety immunogenicity vaccine focus T cell response conserve region HIV-1 proteome . The vaccine use pSG2.HIVconsv DNA ( D ) , MVA.HIVconsv ( M ) Ad35-GRIN ( A ) , deliver regimen AM , DDDAM DeDeDeAM , e indicate electroporation .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity HIV Vaccines Healthy Kenyan Adults</brief_title>
	<detailed_description>The main objective study determine vaccine ' safety immunogenicity African population , strengthen vaccine trial capacity South . HIV-CORE 004 double blind , placebo control randomized Phase I/IIa study design evaluate safety immunogenicity different delivery regimen use three novel HIV-1 vaccine pSG2.HIVconsv DNA ( D ) without electroporation ( e ) , adenovirus Ad35-GRIN ( A ) poxvirus MVA.HIVconsv ( M ) administer intramuscular needle injection heterologous prime-boost regimen . 72 healthy , low-risk , HIV-1-uninfected adult volunteer Nairobi randomly assign one three group , AM , DDDAM DeDeDeAM contain 20 vaccinee 4 placebo recipient . Firstly , study aim evaluate safety tolerability vaccine pSG2.HIVconsv DNA ( D ) without electroporation ( e ) , adenovirus Ad35-GRIN ( A ) poxvirus MVA.HIVconsv ( M ) . Secondly , shall determine effect electroporation DNA priming frequency , durability and/or quality T cell response ( DDDAM v DeDeDeAM ) . Thirdly , shall determine whether prim three DNA vaccination without electroporation affect frequency , durability and/or quality T cell response HIVconsv immunogen compare see AM regimen ( AM v DDDAM/DeDeDeAM ) . As first study combine HIVconsv vaccine African population , pSG2.HIVconsv DNA electroporation , combination two HIVconsv vaccine Ad35-GRIN , trial design pilot study compare different vector combination . The sample size allow detection large response difference volunteer three group , thus , yield data primarily descriptive .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult aged 1850 Willing comply requirement protocol available followup plan duration study . Written informed consent . Willing undergo HIV1 testing , counsel receive test result . All female volunteer must willing undergo urine pregnancy test If sexually active use effective method contraception least 4 month last vaccination . Willing forgo donate blood study . Any relevant abnormality history examination include history immunodeficiency autoimmune disease , use systemic corticosteroid , immunosuppressive , antiviral , anticancer medication , opinion Principal Investigator designee , clinically significant , within previous 6 month . ( Note : use inhale steroid asthma use topical steroid localize skin condition exclude volunteer participation . ) Any clinically significant acute chronic medical condition consider progressive , opinion Principal Investigator designee , would make volunteer unsuitable study . Any following abnormal laboratory parameter ( 1 abnormal test may repeat thought due temporary condition ) : Haematology Haemoglobin &lt; 9.0 g/dl woman &lt; 11.0 g/dl men Absolute Neutrophil Count ( ANC ) ≤ 1000 /mm3 ( ≤ 1 x 109 /l ) Absolute Lymphocyte Count ( ALC ) ≤ 600 /mm3 ( ≤0.6 x 109 /l ) Platelets ≤100,000 /mm3 , ≥ 550,000 /mm3 ( ≤ 100 /l , ≥ 550 /l ) Biochemistry Creatinine &gt; 1.3 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) &gt; 2.5 x ULN Alanine aminotransferase ( ALT ) &gt; 2.5 x ULN Urinalysis Clinically significant abnormal dipstick confirm microscopy : Protein = 2+ Blood = 2+ ( woman : menses ) Confirmed HIV1 HIV2 infection . If female , pregnant plan pregnancy time enrolment 4 month last vaccination ; lactate . Receipt live attenuate vaccine within previous 60 day plan receipt time 60 day vaccination Investigational Medicinal Product ( IMP ) receipt vaccine , include influenza vaccine , within previous 14 day plan receipt time 14 day vaccination IMP . Receipt blood transfusion blood product within previous 6 month . Participation another clinical trial IMP currently within previous 3 month expect participation study . Receipt investigational HIV1 vaccine within last 6 year . History severe severe local systemic reactogenicity event vaccination , history severe severe allergic reaction . Confirmed diagnosis acute chronic hepatitis B virus infection ( spontaneous clearance lead natural immunity , indicated antibody core + antigen , exclusion criterion ) ; confirm diagnosis hepatitis C virus infection ; untreated syphilis . Smallpox vaccination within previous 3 year . Major psychiatric illness previous 3 year . History allergy hypersensitivity latex , chronic skin problem eczema psoriasis , skin subcutaneous tissue thickness &gt; 40 mm assess skin pinch test either deltoid region . Presence implantable device Current use electronic stimulation device . Therapeutic traumatic metal implant either deltoid region . History , know active cardiac disease heart condition care doctor . Note : Slight physiological variation normal rest heart rate ( 60 100 beats/minute ) respiration NOT exclude . History syncope fainting episode within 1 year study entry . Seizure disorder history prior seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>vaccine</keyword>
</DOC>